FDA Advisers Recommend Approval of New Shingles Vaccine — Physician’s First Watch
FDA Advisers Recommend Approval of New Shingles Vaccine
By the Editors
An FDA advisory panel voted 11-0 on Wednesday in favor of approving the Shingrix herpes zoster vaccine for adults aged 50 and older, Reuters reports.
In clinical trials, the new vaccine conferred greater protection against herpes zoster among older adults, relative to the currently marketed zoster vaccine, Zostavax. In particular, 4 years after immunization, Shingrix was about 90% effective in adults older than 70, while the efficacy of Zostavax waned with time, according to Reuters.
The FDA is not required to follow the advice of its advisers, but it usually does.